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Introduction
Approximately 25% of women suffer from a degree of in-
continence, prolapse, or vaginal laxity due to the weakening 
of the pelvic floor after a “normal” delivery [1,2]. There is an 
association between urinary incontinence, pelvic floor muscle 
strength, and the number and type of deliveries [3,4]. During 
a vaginal delivery, it is quite common (15–50% of women 
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may be affected) for the pelvic floor muscles (levator) to be 
damaged to some extent [5-7]. If this condition is not ade-
quately repaired and persists for an extended period of time, 
it can lead to increased risk for pelvic floor dysfunction. After 
delivery, more than 60% of patients recover from pelvic floor 
muscle injuries within 1 year [8]. However, women with per-
sistent levator avulsion show significantly worse deterioration 
patterns in muscle strength, hiatus measurements, and vagi-
nal symptoms such as a loose vagina or lump sensation [8,9]. 
These findings emphasize the importance of proper recovery 
from pelvic floor muscle injuries sustained at birth. Currently, 
we are not aware of any preventive methods; such methods 
could significantly reduce injuries to the pelvic floor muscles 
during pregnancy and childbirth.
Zinc is the second most common trace element in the hu-
man body and is a cofactor for many enzymes [10]. It plays 
a vital role in connective tissue biosynthesis, and we have 
investigated the role of zinc in previous publications [11,12]. 
We have shown that in human vaginal smooth muscle cells, 
20 μM zinc levels have a beneficial effect on the production 
of extracellular components produced by the muscle, which 
thereby increase the levels of collagen and elastin that are 
produced, as well as the amount of smooth muscle. In ad-
dition, animal experiments have demonstrated the impor-
tance of zinc [13,14]. One animal study showed that zinc 
plays an important role in vaginal extracellular matrix (ECM) 
composition: plasma zinc levels were significantly lower in 
buffaloes with antepartum prolapse [14]. Additionally, when 
rats were kept on a diet lacking zinc, the structure of the va-
gina became similar to a menopausal vagina’s structure [13]. 
Another study found that when zinc replacement was per-
formed locally in the vagina, the vaginal ECM regenerated, 
and a vaginal ECM resembling that of juvenile rats was cre-
ated [11]. In humans, tissue zinc levels are significantly lower 
in patients with all types of hernias, and risk factors for the 
development of hernias are similar to those for the develop-
ment of vaginal prolapse [15]. Even if there is no absolute 
zinc deficiency in pregnant women, the risk of peripartum 
and postpartum complications is still increased by zinc serum 
levels that are at the lower end of the normal range [16-18]. 
While maternal zinc levels did not differ before delivery, plas-
ma zinc levels were significantly decreased in women who 
underwent vaginal deliveries, relative to the zinc levels of 
women who received cesarean sections [16]. This is probably 
due to the high stress placed on skeletal and uterine muscles 
during childbirth [16].
The beneficial effects of omega-3 fatty acids in pregnancy 
are well known. It has been shown that omega-3 fatty acids 
can increase the production of muscle proteins, thereby en-
hancing muscle strength [19-22]. Dietary intake of omega-3 
fatty acids increases muscle anabolic signaling activity, there-
by stimulating protein synthesis in muscles [20].
Leucine is an essential amino acid that is also capable of 
stimulating the synthesis of muscle proteins. It enhances 
regeneration and prevents muscle tissue from degradation. 
Leucine can also prevent muscular weakness related to aging 
[23]. Numerous studies have documented leucine’s beneficial 
role in enhancing muscle protein synthesis [23-25].
The aim of this study was to investigate the recovery of 
pelvic floor injuries and their related symptoms after daily 
supplementation with a specially formulated dietary supple-
ment. This supplement was designed to promote the resto-
ration of muscular injuries following delivery and contains 
ingredients of a multivitamin composition that can be taken 
during lactation. The key ingredients of the supplement were 
zinc, leucine, and omega-3 fatty acids.
Materials and methods
We conducted a randomized, double-blind, placebo-con-
trolled trial with a 6-week follow-up period. A 1:1 random-
ization ratio was generated and completed by SAS (SAS In-
stitute, Cary, NC, USA) version 9.4. We enrolled postpartum 
women who underwent a normal prenatal course without 
significant medical comorbidities, and who had a first-time, 
normal vaginal delivery in the Department of Obstetrics 
and Gynecology at the University of Debrecen in Hungary. 
Women were enrolled within 48 hours of delivery, after sign-
ing a written informed-consent form. Exclusion criteria were 
as follows: one or more previous pregnancies with vaginal 
delivery (multipara), multiple gestations, premature birth, 
operative vaginal delivery (other than outlet vacuum deliv-
ery), gestational diabetes, caesarean section, allergy to fish, 
vegetarian lifestyle, history of uterine malformation or prior 
uterine surgery. Furthermore, patients with known zinc or 
copper deficiencies and patients with collagen or connective 
tissue diseases were also excluded.
After enrollment, women were randomized to receive the 
specially formulated dietary supplement (Mommytoo vita-
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min; Fempharma, LLC, Budapest, Hungary) (treatment group) 
or a prenatal vitamin (PNV; control group). Women in the 
treatment group were asked to take the oral dietary supple-
ment every day for 6 weeks. The dietary supplement in the 
treatment group included a daily dose of PNV, 4 g of leucine, 
30 mg of zinc, and 900 mg omega-3 fatty acids (465 mg 
eicosapentaenoic acid and 375 mg docosahexaenoic acid). 
The daily supplementation in control group women consisted 
of a routine PNV.
After randomization, subjects received the dietary supple-
ment in a sealed, uniform box. The completely identical 
boxes were labeled with codes that were not known by re-
searchers participating in the clinical trial. The patients could 
not be identified by the code. Participants did not know what 
kind of preparations they were given (i.e., what the tablets 
looked like in the 2 groups), and were randomly assigned to 
a group without informing them to which group they be-
longed. After enrollment, women were asked to complete 
the Pelvic Organ Prolapse Distress Inventory 6 (POPDI-6) and 
the Urinary Distress Inventory 6 (UDI-6). Serum samples were 
obtained to measure zinc levels in a certified laboratory. At 
the 6 week post-delivery visit, a general gynecological exam 
was performed and a POP-Q measurement was obtained. In 
addition, the strength of the voluntary contractions of the 
vaginal muscles were measured by a perineometer (Peritron; 
Laborie, Williston, VT, USA) in a standardized fashion [26,27]. 
A 3-dimensional (3D) pelvic floor ultrasound was also per-
formed to evaluate defects in the musculus levator ani us-
ing GE Voluson S8 3D ultrasound equipment (GE Medical 
Systems, Chicago, IL, USA). Both the levator hiatus and the 
levator-urethra gap (LUG) was measured as described previ-
ously [28-30]. Serum sample was taken from the participants 
to determine their serum zinc and copper level. Participants 
were asked to complete the POPDI-6 and UDI-6 question-
naires again.
Co-primary outcomes were the measurement of vaginal 
squeeze force by a perineometer and the measurement of 
musculus levator ani defects by ultrasound (LUG) [26-31].
Secondary outcomes were questionnaire (POPD-6 and UDI-
6) results, Pelvic Organ Prolapse Quantification (POP-Q) mea-
surements, a digital survey of pelvic floor muscle strength, 
and serum zinc concentrations. These were performed im-
mediately following delivery and at 6 weeks after delivery.
1. Questionnaires
The POPDI-6 and UDI-6 were used to assess subjective pelvic 
floor symptoms [32]. To specify the severity of pelvic floor 
distress symptoms, patient response options ranged from 0 
(“no symptoms”) to 4 (“quite a bit”). To calculate the score, 
the mean score of answered items within each component 
was multiplied by 25 to obtain the scale score (range 0–100).
Fig. 1. Flow of participants through the randomized clinical trial. Participants were allocated to treatment or control groups.
Completed study and analyzed
(n=26)
Excluded
(n=8)
Randomized
(n=66)
Assessed for eligibility
(n=133)
Excluded
(n=47)
Completed study and analyzed
(n=27)
Excluded
(n=5)
Allocated to control
(n=34)
Allocated to treatment
(n=32)
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2. Statistics
For statistical analyses, we used SigmaStat/SPSS software. 
Descriptive statistics were calculated for all variables of inter-
est. Means and standard deviations (SDs) were calculated for 
continuous outcomes. Frequency and percentage were cal-
culated for categorical outcomes. Student’s t-test was used 
to compare the mean values between the 2 groups. Paired 
t-test was used to compare paired data, which were ob-
tained at baseline and at 6 weeks (zinc levels, question-
naires). Frequencies were analyzed by Fisher’s exact test. This 
study had adequate power to detect a difference after 46 
patients’ enrollment. Power analysis was performed based 
on our pilot study, which revealed that the threshold for a 
weak pelvic floor muscle is ≤17 cm H2O as measured by our 
perineometer. To have a power of 80% and a significance 
level of 5% to detect a 40% difference in the rate of weak 
vaginal squeeze pressure, a sample size of 46 patients was 
required, with 23 patients in each arm of our randomized 
clinical trial (RCT). Statistical significance was defined as a 
P-value <0.05 using 2-tailed tests.
Results
Fig. 1 summarizes the assessment for eligibility, randomiza-
tion, allocation, and exclusions of participants. Of the 113 
women screened, 66 met entry criteria and were randomized 
to treatment or control groups. Fifty-three women completed 
the trial. Of the 47 participants who were excluded, 10 did 
not meet inclusion criteria, and 37 decided not to participate 
in the trial. Thirty-four women were randomly assigned to 
the control group and 32 to the treatment group.
Of the 32 individuals randomly assigned to treatment 
group, 5 did not complete the trial: 2 were lost to follow-
up, 3 withdrew from participation because of minor adverse 
events (1 woman developed a rash, 1 woman could not 
swallow pills, and 1 mother felt that her infant’s vomiting 
was related to the supplement). Of the 34 women ran-
domized to the control group, 8 did not complete the trial: 
4 were lost to follow-up, 2 withdrew consent before taking 
any supplements, 1 developed a minor adverse event (rash), 
and 1 refused any examination at the follow-up visit. In total, 
53 women completed the trial: 26 in the control group and 
27 in the treatment group.
1.  Demographic and baseline characteristics at 
randomization
Demographic and baseline characteristics at randomization 
are presented in Table 1. There were no statistically signifi-
cant differences in the distribution of any of the demograph-
ic variables between the control and treatment groups. The 
majority of women had a mediolateral episiotomy at delivery. 
Birthweight and fetal head circumference were similar be-
tween the control and treatment group.
Table 1. Demographic and clinical characteristics of participants
Characteristics Control group (n=26) Treatment group (n=27) P-value
Age (yr) 28±3 29±3 NS
Gravida 1 (1–3) 1 (1–3) NS
Pre-pregnancy BMI (kg/m2) 21.7±4.6 21.9±3.8 NS
BMI at delivery (kg/m2) 28.3±4.3 26.9±3.3 NS
Estimated gestational age (wk) 38.6±1.4 38.7±1.4 NS
Birthweight (grams) 3,307±401 3,411±111 NS
Head circumference (cm) 33±1 33±1 NS
Length of second stage (min) 27±11 32±13 NS
Episiotomy 25 (96) 25 (92) NS
Epidural 18 (69) 16 (60) NS
Vacuum extraction 0 (0) 3 (11) NS
Breastfeeding 26 (100) 27 (100) NS
Values are presented as mean±standard deviation, median (range) or number (%).
BMI, body mass index; NS, not significant.
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2. Serum zinc levels
We expected that zinc levels would rise in the treatment and 
control groups compared to the baseline values obtained 
within 48 hours after delivery, since both the control and 
treatment group received daily zinc supplementation (15 mg 
vs. 30 mg, respectively). Consistent with the patient-reported 
compliance in both the treatment and control groups, the 
mean zinc levels increased significantly from baseline com-
pared to 6 weeks after delivery (Table 2). Although the mean 
zinc level was 10% higher in the treatment group at 6 weeks 
postpartum compared to the control group, it did not reach 
statistical significance. However, zinc levels on average in-
creased significantly more in the treatment group from base-
line to 6 weeks postpartum compared to the control group 
(mean±SD Δ zinc level increase 0.48±0.24 vs. 0.29±0.20, 
P<0.01).
3. Co-primary outcomes
1)  Vaginal squeeze pressure as measured by perine-
ometer at 6 weeks after delivery
The results obtained by the perineometer are described in 
Table 3. The mean Oxford scale values were similar between 
groups. However, weak pelvic floor muscle strength (defined 
as the mean of 3 vaginal squeeze pressure measurements by 
Peritron perineometer ≤17 cm H2O) was significantly less fre-
Table 2. Serum zinc levels at baseline and 6 weeks postpartum
Characteristics Control group (n=26) Treatment group (n=27) P-value
Zinc level after delivery (mg/L) 0.71±0.19 0.62±0.10 NS
Zinc level 6 weeks postpartum (mg/L) 1.00±0.19 1.10±0.25 NS
P-value <0.01 <0.01 -
Values are presented as mean±standard deviation.
NS, not significant.
Table 3. Measurement of vaginal squeeze pressure by perineometer at 6 weeks postpartum and manual assessment of pelvic floor 
strength on a pelvic exam by palpation (Oxford scale) 
Characteristics
Control group 
(n=26)
Treatment group 
(n=27)
Risk ratio
(95% confidence interval)
P-value
Vaginal squeeze pressure (cm H2O) 21±17 22±13 N/A NS
Oxford scale 3 (1–5) 3 (1–4) N/A NS
Weak vaginal squeeze pressure (≤17 cm H2O; %) 58 28 0.48 (0.23–0.98) 0.03
Values are presented as mean±standard deviation or median (range).
NS, not significant; N/A, not applicable.
Table 4. Levator-urethra gap (LUG) and levator hiatus measured by 3-dimensional transperineal tomographic ultrasound at 6 weeks 
postpartum 
Characteristics
Control group 
(n=26)
Treatment group 
(n=27)
Risk ratio
(95% confidence interval) P-value
Right-sided LUG (mm) 24.9±4.2 21.1±2.9 N/A <0.01
Left-sided LUG (mm) 24.9±3.7 20.1±2.8 N/A <0.01
Levator hiatus (cm2) 17.7±2.7 15.5±2.4 N/A <0.01
Unilateral avulsion (%) 34.6 3.7 0.10 (0.01–0.78) <0.01
Bilateral avulsion (%) 38.4 3.7 0.09 (0.01–0.70) <0.01
Values are presented as mean±standard deviation.
N/A, not applicable.
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quent in the treatment group compared to the control group 
at 6 weeks post-delivery (28% vs. 58%, P=0.03). The risk 
of having a weak vaginal squeeze pressure was reduced by 
52% in the treatment group compared to the control group 
at 6 weeks postpartum (Risk ratio [RR], 0.48; 95% confi-
dence interval [CI], 0.23–0.98; P=0.03).
2)  Levator-urethra gap as measured by 3-dimensional 
transperineal tomographic ultrasound
Both right- and left-sided LUGs were significantly larger in 
the control group compared to the treatment group (Table 4). 
A large LUG (≥25 mm) is a good indicator of a levator muscle 
injury and typically indicates avulsion. Unilateral levator injury 
was defined by an LUG ≥25 mm on at least one side. Uni-
lateral levator avulsion was significantly less frequent in the 
treatment group compared to the control group at 6 weeks 
after delivery (3.7% vs. 34.6%, P<0.01). The presence of 
unilateral levator avulsion was reduced by almost 90% com-
pared to the control group at 6 weeks postpartum (RR, 0.10; 
95% CI, 0.01–0.78).
Bilateral avulsion was defined by LUG ≥25 mm on both 
sides. Similar to unilateral avulsion, bilateral levator avulsion 
was significantly less frequent in the treatment group com-
pared to the control group at 6 weeks after delivery (3.7% 
vs. 38.4%, P<0.01). The presence of bilateral levator avul-
sion was reduced by 90% compared to the control group at 
6 weeks postpartum (RR, 0.09; 95% CI, 0.01–0.70; P<0.01). 
In addition, the levator hiatus was significantly smaller in the 
treatment group compared to the control group at 6 weeks 
after delivery (15.5±2.4 vs. 17.7±2.7, P<0.01).
4. Secondary outcomes
1) Pelvic Organ Prolapse Quantification measurement
The findings of the POP-Q measurement are described in 
Table 5. Anterior vaginal wall prolapse at or beyond the 
hymenal ring was significantly more common in the con-
trol group compared to the treatment group (19% vs. 0%, 
P=0.02). Also, wide genital hiatus (defined as GH ≥4 cm) 
was significantly more frequent in the control group com-
pared to the treatment group at 6 weeks after delivery (46% 
vs. 18%, P=0.01). The risk of wide genital hiatus was almost 
3 times higher in the control group compared to the treat-
ment group 6 weeks postpartum (RR, 2.95; 95% CI, 1.19–
7.30; P=0.01).
2)  Validated questionnaires (Pelvic Organ Prolapse 
Distress Inventory 6, Urinary Distress Inventory 6)
The mean POPDI-6 and UDI-6 standardized scale scores were 
similar between the control and treatment groups (6.6±13.0 
vs. 4.6±6.3, P=0.46 and 18.4±16.8 vs. 22.3±14.5, P=0.60). 
However, significantly more women reported bothersome 
bulge symptoms (Q#3 on POPDI-6) in the control group com-
pared to the treatment group at 6 weeks postpartum (19% 
vs. 0%, P=0.02). In addition, the mean standardized POPDI-6 
score significantly improved in the treatment group at 
6 weeks compared to the baseline score (4.6±6.3 vs. 1.7±3.9, 
P=0.02) but did not improve significantly in the control group 
(6.6±13.0 vs. 2.2±3.5, P=0.11). The mean standardized UDI-
6 score significantly improved in both the control and the 
treatment groups by 6 weeks compared to the baseline score 
(18.4±16.8 vs. 3.8±5.5, P<0.01 [control] and 22.3±14.5 vs. 
5.4±9.7, P<0.01 [treatment group]).
Discussion
We are the first to report the effects of a specially formulated 
postpartum recovery supplement on the recovery of pelvic 
floor function after vaginal delivery. We found that daily 
supplementation resulted in improved recovery of the pelvic 
floor after a normal vaginal delivery. Previous publications 
have showed that after delivery, pelvic floor muscle injuries 
recover within 1 year, in more than 60% of cases [8]. Howev-
Table 5. Pelvic Organ Prolapse Quantification (POP-Q) measure-
ment of women at 6 weeks postpartum
Characteristics
Control 
group (n=26)
Treatment 
group (n=27)
P-value
Aa −1.40±1.00 −1.63±0.80 NS
Ba −1.40±1.00 −1.63±0.80 NS
C −6.00±0.80 −6.20±0.90 NS
GH 3.56±0.70 3.40±0.70 NS
PB 2.67±0.50 2.56±0.40 NS
TVL 9.80±0.70 9.80±0.80 NS
Ap −1.73±0.90 −1.70±0.90 NS
Bp −1.73±0.90 −1.70±0.90 NS
D −7.50±3.20 −7.80±0.94 NS
NS, not significant.
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er, women with persistent levator avulsion show significantly 
worse deterioration patterns in muscle strength, hiatus mea-
surements, and vaginal symptoms (e.g., loose vagina or lump 
sensations) [8,9]. These findings emphasize the importance 
of proper recovery from pelvic floor muscle injuries sustained 
at delivery.
Pelvic floor muscle injuries have been linked to anterior and 
central compartment prolapse and likely represent the miss-
ing link between delivery and the development of prolapse. 
A levator avulsion seems to increase the risk of significant 
anterior and central compartment prolapse by 3-fold [33]. 
Our findings are in agreement with prior observations. We 
have found that anterior vaginal wall prolapse at or beyond 
the hymenal ring was significantly more common in the con-
trol group compared to the treatment group. This may be 
explained by the fact that we found that significantly larger 
LUG in the control group was an indicator of more levator 
avulsion, which caused more anterior vaginal wall prolapse. 
In addition, a wide genital hiatus (defined as GH ≥4 cm) was 
significantly more frequent in the control group compared 
to the treatment group at 6 weeks after delivery also likely 
the result of the presence of levator injuries. Similar to the 
presence of significant anterior vaginal wall prolapse, bother-
some prolapse symptoms were more common in the control 
group.
Vaginal squeeze pressure has been previously used as a 
marker for pelvic floor function [34]. Levator injury has been 
associated with weaker pelvic floor muscle contraction mea-
sured with palpation, perineometry, and ultrasound [35]. 
Weak vaginal squeeze pressure has been associated with 
more anterior compartment prolapse and with minor and 
major avulsion [9]. Weak pelvic floor muscle strength (defined 
as the mean of 3 vaginal squeeze pressure measurements by 
Peritron perineometer ≤17 cm H2O) was significantly less fre-
quent in our treatment group compared to the control group 
at 6 weeks after delivery, likely secondary to less levator in-
jury being present.
We believe that our specially formulated postpartum sup-
plement contributed to the faster and superior recovery of 
the pelvic floor, secondary to the special composition of the 
supplement. Zinc serum levels have been shown to signifi-
cantly decrease after vaginal delivery, but not after elective 
cesarean sections [16]. Our supplement contained higher 
doses of zinc compared to the control group. Despite no dif-
ference in the mean serum zinc levels between the control 
and treatment group at 6 weeks, zinc levels on average in-
creased significantly more in the treatment group from base-
line to 6 weeks postpartum compared to the control group. 
In addition, our supplement contained high doses of the 
essential amino acid leucine. Leucine is the only nutritional 
amino acid capable of stimulating the synthesis of muscle 
proteins [24]. It is directly involved in protein synthesis as it 
directly stimulates protein synthesis in muscles, but it has not 
been shown to contribute to pelvic floor recovery [23-25]. 
The beneficial effect of omega-3 fatty acids in pregnancy is 
well known. In humans, it has been shown that omega-3 
fatty acids can increase the production of muscle proteins, 
thereby enhancing muscle strength [19-21].
Our findings indicate that the special composition of our 
supplement containing all 3 key ingredients (zinc, leucine 
and omega-3 fatty acid) in a unique ratio may be responsible 
for the observed beneficial effects on pelvic floor recovery. 
The composition of the supplement was based on the toler-
able upper intake level (UL) of zinc, which is 40 mg. The UL 
represents the maximum daily intake that is unlikely to cause 
adverse health effects. For this reason, women took 30 mg 
of zinc as a supplement to the normal dietary intake, but not 
exceeding the UL of 40 mg per day. Leucine was tested pre-
viously in doses up to 10 gm per day and found to be safe 
[23-25]. One of the main problems with leucine supplemen-
tation is the large amounts required. Our aim was to identify 
the smallest dose possible that was still effective for our 
postpartum women. Previously, it was shown that omega-3 
fatty acids can increase the production of muscle proteins 
and that 900 mg is a safe well-established dose. In addition, 
omega-3 fatty acids have been tried in clinical trials at doses 
up to 4 gm a day [19-22].
The strength of this study was its randomized nature and 
that it is the first trial to test the effects of a food supple-
ment on the recovery of postpartum pelvic floor function. An 
important strength of the study was that study participants 
were blinded to the allocation. Another strength of this 
RCT is that the investigators performing the perinoemetry, 
the transperineal ultrasound, and the pelvic floor assess-
ment were also blinded to the allocation. In addition, the 
measurements of LUG were performed prior to breaking 
the randomization. Also, a strength of this study was our 
participants’ high compliance in taking the supplements, as 
reflected by the significant elevation of zinc serum levels in 
both the treatment and control groups. Previous research has 
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revealed that after vaginal delivery, zinc levels are expected to 
decrease significantly. However, in our study population, zinc 
levels increased significantly, suggesting patient compliance 
with the allocated supplements [16]. The trial discontinua-
tion rate in the treatment group was not statistically different 
compared to the control group (15.6% vs. 23.5%, P>0.05). 
The up to 80% attrition rate is comparable to that of other 
randomized controlled trials.
The main limitations of our study include the lack of ca-
pability to detect differences in several secondary outcomes 
and the relatively low number of women enrolled. Another 
was that we did not assess levator injury either by ultrasound 
or by perineometry immediately after delivery. In our experi-
ence, it is quite difficult to accurately assess levator injuries 
immediately after delivery, secondary to the tissue swelling, 
edema, and pain that may be involved with the examina-
tions. A further weakness of our study was the homogenous 
non-diverse study population, which can be explained by the 
fact that the vast majority of the local population belongs to 
only one race and ethnicity. Another limitation to the gener-
alizability of this study is the fact that over 90% of women 
had an episiotomy during delivery. Our trial did not provide 
accurate insight into the mechanism of action of the supple-
ment. It is possible that the observed effects are secondary 
through an anti-inflammatory process rather than a direct 
effect on the levator muscles and ECM.
In summary, patients receiving the specially formulated 
postpartum recovery supplement showed improved recovery 
in pelvic floor function after vaginal delivery. Postpartum 
women who received the supplement were less likely to have 
weak vaginal squeeze pressure, presence of levator muscle 
injury, anterior vaginal prolapse at or beyond the hymenal 
ring, bothersome bulge symptoms, and wide genital hiatus 
compared to women who received a PNV only at 6 weeks 
after vaginal delivery. Further research is needed to validate 
our findings in a more diverse and larger population.
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